DBT阴性后补充超声筛查的增量价值与假阳性负担
回顾性分析2014-2024年单中心102,993例DBT与超声同步筛查,其中6647例DBT阴性但超声异常。超声增量癌检出率为1.0/1000,PPV1为1.5%,假阳性率高达98.5%。结论提示DBT时代补充超声增量有限,支持转向基于风险的补充筛查策略。
要点
- DBT阴性者补充超声癌检出率仅1.0/1000,报告时应参考该增量价值
- 超声异常者假阳性率98.5%,活检假阳性率94.8%,避免过度提示恶性
- 检出的癌症中89.9%为浸润性癌,一旦发现应尽早病理确认
核心结论
- DBT时代,阴性乳腺摄影后补充超声仅提供适度的癌检增幅,代价是高假阳性率和活检率
- 结果支持向基于风险的筛查策略转变,对致密乳腺更多依赖MRI或对比增强乳腺摄影作为补充筛查
研究设计与样本
- 单中心回顾性研究,纳入2014-2024年所有同步接受DBT乳腺摄影和超声筛查的女性
- 研究对象为DBT阴性(BI-RADS 1或2)且超声异常(BI-RADS 0、3、4或5)的患者
- 总筛查量为102,993次同步检查,研究队列为6647例(6.5%)DBT阴性但超声异常者
关键影像表现/征象
- 6647例DBT阴性但超声异常者中检出99例癌症
- 1917例接受活检者中99例为恶性,89例为浸润性组织学类型
诊断标准与关键数值
- 增量超声癌检出率为1.0/1000筛查人次,PPV1为1.5%
- 超声假阳性率为98.5%,活检PPV3为5.2%,活检假阳性率为94.8%
- 乳腺癌检出率在不同乳腺密度间无显著差异
- 假阳性率随年龄增加而增高,OR为1.05,p<0.001
临床应用与阅片要点
- 对DBT阴性但超声异常的致密乳腺患者,报告时应认识到阳性预测值极低,避免过度解读
- 超声检出的癌症以浸润性为主,提示超声发现的实性占位仍需积极活检确认
局限性
- 单中心回顾性设计可能限制结果外推
- 既往证据多早于DBT广泛应用,故补充超声的旧数据可能不适用于当前DBT时代
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Screening ultrasound has historically been used as an adjunct to mammography in women with dense breasts. However, most prior evidence predates widespread adoption of digital breast tomosynthesis (DBT), which has substantially improved cancer detection and reduced recall rates.
OBJECTIVE: To evaluate the incremental diagnostic yield and false-positive burden of screening ultrasound in women with negative DBT screening examinations.
METHODS: This retrospective study included all women undergoing concurrent screening mammography with DBT and screening ultrasound at a single academic center from 2014-2024. The study cohort consisted of patients with negative DBT (BI-RADS 1 or 2) and concurrent abnormal screening ultrasound (BI-RADS 0, 3, 4, or 5). Cancer detection rate (CDR), abnormal interpretation rate (AIR), false-positive rate (FPR), and positive predictive values (PPV1 and PPV3) were calculated. Subgroup analyses were performed by age and breast density.
RESULTS: Among 102,993 concurrent screening examinations, 6647 (6.5%) had negative DBT but abnormal ultrasound assessment. This cohort yielded 99 cancers, corresponding to an incremental ultrasound CDR of 1.0 per 1000 screened and PPV1 of 1.5%. The false-positive rate of screening ultrasound was 98.5%. Among 1917 resulting biopsies, 99 were malignant (PPV3 5.2%; false-positive biopsy rate of 94.8%), the majority of which were invasive histologic type (89/99, 89.9%). Cancer detection did not differ significantly by breast density, while false positives increased with age (OR 1.05, p < 0.001).
CONCLUSION: In the DBT era, screening ultrasound after negative mammography provides a modest increase in cancer detection at the cost of high false-positive and biopsy rates. These findings support a shift toward risk-based screening strategies and greater reliance on vascular-based modalities such as MRI or contrast-enhanced mammography (CEM) for supplemental screening in women with dense breasts.
引用
- Dodelzon, Shah, Intorcia, et al. Incremental Cancer Detection and False-Positive Burden of Screening Ultrasound After Negative Digital Breast Tomosynthesis: A 10-Year, 100,000-Examination Retrospective Study. Acad Radiol. 2026. PMID: 42457499. doi:10.1016/j.acra.2026.06.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。